These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22005540)

  • 1. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
    Sadiq AA; Geynisman DM; Salgia R
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1810-1. PubMed ID: 22005540
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
    Sadiq AA; Salgia R
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S372-4. PubMed ID: 23160322
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.
    Riess JW; Neal JW
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1797-8. PubMed ID: 22005534
    [No Abstract]   [Full Text] [Related]  

  • 4. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer.
    Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Faus-Dáder MJ; Calleja-Hernández MÁ
    Pharmacol Res; 2015 Dec; 102():90-106. PubMed ID: 26413995
    [No Abstract]   [Full Text] [Related]  

  • 5. MET as a possible target for non-small-cell lung cancer.
    Sadiq AA; Salgia R
    J Clin Oncol; 2013 Mar; 31(8):1089-96. PubMed ID: 23401458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells.
    To C; Seiden I; Liu N; Wigle D; Tsao MS
    Exp Cell Res; 2002 Feb; 273(1):45-53. PubMed ID: 11795945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
    Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
    Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.
    Remon J; Morán T; Majem M; Reguart N; Dalmau E; Márquez-Medina D; Lianes P
    Cancer Treat Rev; 2014 Feb; 40(1):93-101. PubMed ID: 23829935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115.
    Kunii E; Ozasa H; Oguri T; Maeno K; Fukuda S; Uemura T; Takakuwa O; Ohkubo H; Takemura M; Niimi A
    Anticancer Res; 2015 Oct; 35(10):5241-7. PubMed ID: 26408683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
    Surati M; Patel P; Peterson A; Salgia R
    Expert Opin Biol Ther; 2011 Dec; 11(12):1655-62. PubMed ID: 22047509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-MET inhibitors in the treatment of lung cancer.
    Goździk-Spychalska J; Szyszka-Barth K; Spychalski L; Ramlau K; Wójtowicz J; Batura-Gabryel H; Ramlau R
    Curr Treat Options Oncol; 2014 Dec; 15(4):670-82. PubMed ID: 25266653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET...
    Scagliotti GV; Di Maio M
    Ann Oncol; 2015 Oct; 26(10):2007-9. PubMed ID: 26265168
    [No Abstract]   [Full Text] [Related]  

  • 18. α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells.
    Michikoshi H; Nakamura T; Sakai K; Suzuki Y; Adachi E; Matsugo S; Matsumoto K
    Cancer Lett; 2013 Jul; 335(2):472-8. PubMed ID: 23507559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET signaling: novel targeted inhibition and its clinical development in lung cancer.
    Feng Y; Thiagarajan PS; Ma PC
    J Thorac Oncol; 2012 Feb; 7(2):459-67. PubMed ID: 22237263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.